|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1). | Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel | 2012 | World Journal of Gastroenterology2012，18，33： | 3 |
| 2 | Phase Ⅱ study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastatic gastric cancer patients显示文摘 | Louvet C André T Tigaud JM | 2002 | Journal of Clinical Oncology2002，，23： | 2 |
| 3 | Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids显示文摘 | Alexandre Louvet Emmanuel Diaz Sébastien Dharancy Hugues Coevoet Frédéric Texier Thierry Thévenot Pierre Deltenre Valérie Canva Christophe Plane Philippe Mathurin | 2007 | Journal of Hepatology2007，，3： | 2 |
| 4 | Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients显示文摘 | Louvet C Andre T Tigaud JM | 2002 | J Clin Oneol2002，20，23： | 1 |
| 5 | A review of GEBCOD trial of bimonthly leucovorin plus 5-fluorouracil 48h continuous infusion in advanced colorectal cancer: evolutions ofa regimen 显示文摘 | De Gramont A Louvet C Andre T | 1998 | Eur J Cancer1998，34，5： | 1 |
| 6 | Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase Ⅲ trial显示文摘 | Louvet C Labianca R Hammel P | 2005 | J Clin Oncol2005，23，15： | 1 |
| 7 | Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phase Ⅲ trial显示文摘 | Louvet C Labianca R Hammel P | 2005 | Clin Oncol2005，23，15： | 1 |
| 8 | The relationship between bispectral index and propofol during target-controlled infusion anesthesia: a comparative study between children and young adults显示文摘 | Rigouzzo A Girauh L Louvet N | 2008 | Anesth Analg2008，106，： | 1 |
| 9 | ERM proteins: from cellular architecture to cell signaling显示文摘 | Louvet - Vallee S | 2000 | Biol Cell2000，92，： | 1 |
| 10 | Oxaliplatin for the treatment of advanced colorectal cancer future directions显示文摘 | Ducreux M Louvet C Bekradda M | 2003 | Semin Oncol2003，25，25： | 1 |
| 11 | Phase Ⅱ study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastatic grastric cancer patients显示文摘 | Louvet C Andre T Tigaud JM | 2002 | J Clin Oncol2002，20，： | 1 |
| 12 | Oxaliplatin folinic acid and 5-fluorouracil in pretreated patients with metastatic advanced cancer 显示文摘 | De Gramont A Tournigand C Louvet C | 1997 | Rev Med Int1997，18，10： | 1 |
| 13 | Phase Ⅱ study ofoxaliplatin, fluorouacil, and folinic acid in locally advanced or metastatic gastric cancer patiant 显示文摘 | Louvet C Andre T tigaud JM | 2002 | J Clin Oncol2002，20，23： | 1 |
| 14 | Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission显示文摘 | Tournigand C Louvet C Molitor JL | 2003 | Gynecol Oncol2003，91，2： | 1 |
| 15 | Role and value of oxaliplatin in metastatic colorectal cancers显示文摘 | Louvet C de Gramont | 1997 | Rev Med Interne1997，18，4： | 1 |
| 16 | Phase Ⅱ study of oxaliplatin,fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients 显示文摘 | Louvet C Andre T Tigaud JM | 2002 | J Clin Oncol2002，20，： | 1 |
| 17 | Phase 11 study of oxaliplatin, fluo- rouracil, and folinic acid in Loeallg advanced or metastativ gastrig cancer patients显示文摘 | Louvet G Andre T Tiguud JM | 2002 | Clin 0ncol2002，20，23： | 1 |
| 18 | Adenocarcinoma of the pancreas: General characteristics显示文摘 | Andre T Balosso J Louvet C | 1998 | Presse-Med1998，27，11： | 1 |
| 19 | Identification of a new member of the CD20/FcepsilonRIbeta family overexpressed in tolerated allografts 显示文摘 | Louvet C Chiffoleau E Heslan M | 2005 | Am J Transplant2005，5，9： | 1 |
| 20 | Phase Ⅱ study of oxaliplatin, fluorouracil and folinc acid in locally advanced or metastatic gastric cancer patients 显示文摘 | Andre T Tigaudj M | 2002 | Clin Oncol2002，20，23： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员